Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Bempedoic Acid vs Nilemdo
NCT06923956Phase 1Completed
- Sponsor
- Humanis
- Start
- Dec 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bempedoic acid in hypercholesterolemia, mixed dyslipidemia and cardiovascular diseases (CVD) (2 arms), sponsored by Humanis. Primary endpoints: Maximum measured plasma concentration at 72 hours and Area under the plasma concentration-time curve to last quantifiable concentration at 72 hours. Started Dec 2024; status: completed.
02
Drugs
bempedoic acid
03
Conditions
hypercholesterolemiamixed dyslipidemiacardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT06923956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06923956.